药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

AZ的Forxiga将用于I型糖尿病患者

2018-03-05 MedSci MedSci原创

AZForxigaI型糖尿病
关注

欧洲药品管理局已经接受阿斯利康公司（AZ）提交Forxiga作为I型糖尿病治疗药物的申请。该事件包含来自III期DEPICT临床计划的数据，该数据显示，与安慰剂相比，Forxiga作为I型糖尿病控制不佳的患者的可调胰岛素口服辅助药物，在24周和52周时可显着降低HbA1c，体重和每日胰岛素总量。在安全性方面，除了更多数量的糖尿病酮症酸中毒（DKA）事件（已知在I型糖尿病患者中发生频率更高）之外，该


欧洲药品管理局已经接受阿斯利康公司（AZ）提交Forxiga作为I型糖尿病治疗药物的申请。

该事件包含来自III期DEPICT临床计划的数据，该数据显示，与安慰剂相比，Forxiga作为I型糖尿病控制不佳的患者的可调胰岛素口服辅助药物，在24周和52周时可显着降低HbA1c，体重和每日胰岛素总量。

在安全性方面，除了更多数量的糖尿病酮症酸中毒（DKA）事件（已知在I型糖尿病患者中发生频率更高）之外，该药物的特征与用于II型糖尿病患者的特征相一致，AZ称。

Forxiga是2012年以来在欧洲上市的第一类SGLT-2抑制剂，用于II型糖尿病患者，作为单药治疗和作为改善血糖水平的联合疗法的一部分，同时还具有减压和减肥的功效。

通过此次提交，该药物可能成为该地区批准用于治疗I型糖尿病的第一种选择性SGLT-2抑制剂，作为胰岛素口服治疗的辅助药物，"有助于解决该患者人群中重大未满足的需求"， 该公司指出。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1714767, encodeId=9dea1e14767fd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Sep 17 14:17:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694136, encodeId=d74916941364d, content=<a href='/topic/show?id=3b7fe60915' target=_blank style='color:#2F92EE;'>#Forxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7609, encryptionId=3b7fe60915, topicName=Forxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d92c29562813, createdName=xuyong533, createdTime=Fri Jul 20 03:17:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474456, encodeId=121114e44567f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503907, encodeId=66e0150390e68, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293310, encodeId=79f3293310c0, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 05 21:52:50 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-09-17 12498e5fm22(暂无昵称)

    #AZ#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1714767, encodeId=9dea1e14767fd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Sep 17 14:17:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694136, encodeId=d74916941364d, content=<a href='/topic/show?id=3b7fe60915' target=_blank style='color:#2F92EE;'>#Forxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7609, encryptionId=3b7fe60915, topicName=Forxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d92c29562813, createdName=xuyong533, createdTime=Fri Jul 20 03:17:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474456, encodeId=121114e44567f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503907, encodeId=66e0150390e68, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293310, encodeId=79f3293310c0, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 05 21:52:50 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-07-20 xuyong533

    #Forxiga#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1714767, encodeId=9dea1e14767fd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Sep 17 14:17:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694136, encodeId=d74916941364d, content=<a href='/topic/show?id=3b7fe60915' target=_blank style='color:#2F92EE;'>#Forxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7609, encryptionId=3b7fe60915, topicName=Forxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d92c29562813, createdName=xuyong533, createdTime=Fri Jul 20 03:17:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474456, encodeId=121114e44567f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503907, encodeId=66e0150390e68, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293310, encodeId=79f3293310c0, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 05 21:52:50 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-07 xue8604

    #糖尿病患者#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1714767, encodeId=9dea1e14767fd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Sep 17 14:17:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694136, encodeId=d74916941364d, content=<a href='/topic/show?id=3b7fe60915' target=_blank style='color:#2F92EE;'>#Forxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7609, encryptionId=3b7fe60915, topicName=Forxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d92c29562813, createdName=xuyong533, createdTime=Fri Jul 20 03:17:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474456, encodeId=121114e44567f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503907, encodeId=66e0150390e68, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293310, encodeId=79f3293310c0, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 05 21:52:50 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-07 yibei

    #IgA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1714767, encodeId=9dea1e14767fd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Mon Sep 17 14:17:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694136, encodeId=d74916941364d, content=<a href='/topic/show?id=3b7fe60915' target=_blank style='color:#2F92EE;'>#Forxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7609, encryptionId=3b7fe60915, topicName=Forxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d92c29562813, createdName=xuyong533, createdTime=Fri Jul 20 03:17:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474456, encodeId=121114e44567f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503907, encodeId=66e0150390e68, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Wed Mar 07 11:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293310, encodeId=79f3293310c0, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Mar 05 21:52:50 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-05 1e0f8808m18(暂无匿称)

    好文章.学习了.

    0